Cullinan Therapeutics Inc. 宣布，其药物审评的关键时间节点——处方药用户费用法案（PDUFA）目标行动日期已确定为2027年2月27日。这一日期标志着美国食品药品监督管理局（FDA）完成对该公司新药申请审查的最终期限。
Cullinan Therapeutics Inc. 宣布，其药物审评的关键时间节点——处方药用户费用法案（PDUFA）目标行动日期已确定为2027年2月27日。这一日期标志着美国食品药品监督管理局（FDA）完成对该公司新药申请审查的最终期限。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.